Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Gilberto de Castro, Byoung Chul Cho, Yi‐Long Wu et al.|Journal of Clinical Oncology|2022

Cited by 334